13. 多発性硬化症/視神経脊髄炎 Multiple sclerosis/Neuromyelitis optica Clinical trials / Disease details


臨床試験数 : 3,342 薬物数 : 2,380 - (DrugBank : 407) / 標的遺伝子数 : 266 - 標的パスウェイ数 : 240

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2005-005592-14-DE
(EUCTR)
27/07/200612/05/2006Double blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision ProtectDouble blind, placebo-controlled study to determine the safety and efficacy of erythropoietin as an add-on therapy to methylprednisolone in subjects with acute autoimmune optic neuritis (VISION PROTECT) - Vision Protect Multiple sclerosis (MS) is a chronic disease of the central nervous system.Optic neuritis represents one of the most common and frequently the first clinical manifestation of MS. Optic neuritis is mainly characterized by a subacute loss of vision.Trade Name: Erypo/Erypo FS
Product Name: Erypo/Erypo FS
INN or Proposed INN: Epoetin alfa
Other descriptive name: Epo
Trade Name: Urbason solubile forte 1000mg
Product Name: Methylprednisolone
INN or Proposed INN: Methylprednisolon-21-hydrogensuccinat, Natriumsalz
IFSgGmbH, Institute for clinical researchNULLNot RecruitingFemale: yes
Male: yes
Germany